NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQ:CDLX) on behalf of Cardlytics stockholders. Our investigation concerns whether Cardlytics has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On August 7, 2024, Cardlytics announced its second quarter 2024 financial results, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million. The Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.
On this news, Cardlytics’ stock price fell $3.94 per share, or 57.10%, to close at $2.96 per share on August 8, 2024.
If you purchased or otherwise acquired Cardlytics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
